Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W. Friedberg, Christopher A. Yasenchak, Rodolfo Bordoni et al.|Blood|2023Cited by 42
Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma PatientsChristopher A. Yasenchak, Jonathan W. Friedberg, Timothy Larson et al.|Blood|2020Cited by 16
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.Jonathan W. Friedberg, Christopher A. Yasenchak, Andres Forero‐Torres et al.|Journal of Clinical Oncology|2018Cited by 4
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.Christopher A. Yasenchak, Jonathan W. Friedberg, Rodolfo Bordoni et al.|Journal of Clinical Oncology|2020Cited by 3
Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)Christopher A. Yasenchak, J.T. Beck, Rodolfo Bordoni et al.|Blood|2022Cited by 2